At Kisbee Therapeutics, we are engineering recombinant lipoproteins to target the core biological systems underlying neurodegenerative diseases. Our work represents a novel approach to address the problem of lipid dysregulation observed across many CNS (central nervous system) diseases.
Genetically Validated Approach to Restore Lipid Homeostasis
A growing body of scientific evidence has linked dysfunctional lipid biology to the onset and severity of neurodegenerative disease.
Human genetics has shown that ineffective lipoprotein function as well as mutations in lipid transport genes are central drivers of neurodegeneration. Failure to properly regulate lipid transport between neurons, astrocytes, and microglia leads to excitotoxicity, impaired debris clearance, protein accumulation, inflammation, and reduced lysosomal function, all hallmarks of many neurodegenerative diseases.
By use of our highly optimized, engineered lipoproteins, also known as Kisbee Discs, we are able to intervene and restore lipid homeostasis – gathering and transporting lipids to where they are needed.
Kisbee is focused on advancing programs where we can use biomarkers to connect relevant biology in genetically defined patient populations to improve our ability to demonstrate efficacy and to further characterize the potential therapeutic benefit of our approach. Alzheimer’s disease, along with several other rare, chronic, and acute neurodegenerative conditions, are in focus for initial therapeutic development efforts.
At Kisbee, we have a shared mission with the patient communities we serve to develop new and impactful therapies. We know this mission is best achieved by working together and by having the patient’s perspective of the diseases we are researching.
To listen, really listen, to the patient communities we serve to understand unmet needs and your lived experience
To be transparent about our work
To actively partner with advocacy organizations globally throughout the drug development process
If you have questions or would like to connect with a member of our patient advocacy team, please contact us at patients@kisbeetx.com
Meet the experts behind our vision
Join us in creating a new class of therapeutics for neurodegenerative disease
Kisbee is developing lipid-based therapeutics for neurodegenerative diseases and CNS injuries by bringing together passionate scientists and drug developers. Our diverse experiences and perspectives enable us to support and challenge one another, fostering care, respect, and collaboration. New ideas and innovation fuel us. Science and data guide us. Novel challenges and opportunities bring out our best. We are passionate and driven, and we aspire to overcome obstacles with creativity and careful risk-taking, striving to make a difference for patients.
We show up, we speak with honesty and deliver what we promise. We are confident in one another’s capabilities, display integrity in all things, and assume best intent knowing that we each keep everyone’s best interests at heart
We embrace our different backgrounds, experiences, and viewpoints to strengthen our fabric and enhance our outcomes. Our interactions are driven by universal compassion, so we act with humility and a willingness to understand everyone’s perspective
We leverage our relentless passion for our patients, our business, and our science by creatively looking at things through a different lens, humbly considering alternatives, and remaining eager to learn
We share what we should, when we should. We trust each other to demonstrate sound discernment and to honor the best interests of the individuals when sharing
We exercise mature judgment so we’re entrusted to think, experiment, and discover for ourselves. We’re not afraid to take informed risks, embrace challenges, and push boundaries in order to grow Kisbee and support patients
We are actively hiring across a range of roles in R&D, HR, Finance, and Operations. To inquire about open roles, please email recruiting@kisbeetx.com
Jennifer Lippincott-Schwartz received her B.A. from Swarthmore College, her M.S. in Biology from Stanford University, and her PhD in Biochemistry from Johns Hopkins University. She did post-doctoral training at the National Institutes of Health (NIH) under the mentorship of Dr. Richard Klausner and served as Chief of the Section on Organelle Biology in the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development at NIH until 2016. She is currently group leader at Janelia Farm Research Campus, Ashburn, VA.
Lippincott-Schwartz's research uses live cell imaging approaches to analyze the spatio-temporal behavior and dynamic interactions of molecules and organelles in cells. Her group has pioneered the use of green fluorescent protein (GFP) technology for quantitative analysis and modeling of intracellular protein traffic and organelle biogenesis in live cells and embryos, providing novel insights into cell compartmentalization, protein trafficking and organelle inheritance. Most recently, her research has focused on the development and use of photoactivatable fluorescent proteins, which ‘switch on’ in response to light. One application of these proteins she has put to use is photoactivated localization microscopy, (i.e., PALM), a superresolution imaging technique that enables visualization of molecule distributions at high density at the nano-scale.
Her work has been recognized with election to the National Academy of Sciences (2008) and the National Institute of Medicine (2009), and with the Royal Microscopy Society Pearse Prize (2010) and the Society of Histochemistry Feulgen Prize (2001). Dr. Lippincott-Schwartz is currently Editor for Current Protocols in Cell Biology and The Journal of Cell Science and is on the editorial boards of Cell, Physiology and Integrative Biology. She is President-elect of the American Society of Cell Biology and has had leadership roles in the Biophysical Society. She serves on the advisory board for the Searle Scholar Program and scientific review board of Howard Hughes Medical Institute, and is a non-resident Faculty Fellow of the Salk Institute, La Jolla, CA.
